Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk

American Journal of Ophthalmology

Volumn 150, Issue 2, 2010, Pages 179-184

  Chatel, Marc Antoine ^a   Larkin, Daniel F P ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; DEXAMETHASONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISOLONE; RAPAMYCIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; ALLOTRANSPLANTATION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; VISUAL ACUITY;

ADULT; AGED; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77952827770     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.03.010     Document Type: Article

References (23)

1. K.A. Williams, A.J. Esterman, and C. Bartlett How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis Transplantation 81 6 2006 896 901
2. D.J. Coster, and K.A. Williams The impact of corneal allograft rejection on the long-term outcome of corneal transplantation Am J Ophthalmol 140 6 2005 1112 1122
3. A. Vail, S.M. Gore, and B.A. Bradley Influence of donor and histocompatibility factors on conreal graft outcome Transplantation 58 11 1994 1210 1216
4. The Collaborative Corneal Transplantation Studies Research Group Effectiveness of histocompatibility matching in high-risk corneal transplantation Arch Ophthalmol 110 10 1992 1392 1403
5. R.M. Egan, C. Yorkey, and R. Black Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site J Immunol 157 6 1996 2262 2271
6. K. Okada, H.K. Mishima, and M.M. Kawano Involvement of CD8+ RT1B+ and CD4+ RT1B+ cells of cervical lymph nodes in the immune response after corneal transplantation in the rat Jpn J Ophthalmol 41 4 1997 209 216
7. S. Yamagami, and M.R. Dana The critical role of lymph nodes in corneal alloimmunization and graft rejection Invest Ophthalmol Vis Sci 42 6 2001 1293 1298
8. J.C. Hill Systemic cyclosporine in high-risk keratoplasty Short- versus long-term therapy Ophthalmology 101 1 1994 128 133
9. T. Reinhard, R. Sundmacher, and P. Heering Systemic ciclosporin A in high-risk keratoplasties Graefes Arch Clin Exp Ophthalmol 234 Suppl 1 1996 S115 S121
10. A.C. Poon, J.E. Forbes, and J.K.G. Dart Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study Br J Ophthalmol 85 12 2001 1464 1469
11. S. Rumelt, V. Bersudsky, T. Blum-Hareuveni, and U. Rehany Systemic cyclosporine A in high failure risk, repeated corneal transplantation Br J Ophthalmol 86 9 2002 988 992
12. A. Joseph, D. Raj, V. Shanmuganathan, R.J. Powell, and H.S. Dua Tacrolimus immunosuppression in high-risk corneal grafts Br J Ophthalmol 91 1 2007 51 55
13. T. Reinhard, A. Reis, and D. Bhringer Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial Graefes Arch Clin Exp Ophthalmol 239 5 2001 367 372
14. F. Birnbaum, A. Reis, and D. Bohringer An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty Transplantation 81 5 2006 767 772
15. T.H. Flynn, N.A. Mitchison, S.J. Ono, and D.F.P. Larkin Aqueous humour alloreactive cell phenotypes, cytokines and chemokines in corneal allograft rejection Am J Transplant 8 7 2008 1537 1543
16. A.M. Woltman, S.W. van der Kooij, and P.J. Coffer Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression Blood 101 4 2003 1439 1445
17. S. Heidt, D.L. Roelen, and C. Eijsink Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin Transplantation 86 9 2008 1292 1300
18. M.H. Cooper, S.H. Gregory, T.E. Starzl, and E.J. Wing Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors Transplantation 57 3 1994 433 439
19. A. Mercalli, V. Sordi, and M. Ponzoni Rapamycin induces caspase-independent cell death in human monocytes Am J Transplant 6 6 2006 1331 1341
20. T.W. Olsen, N.M. Benegas, and A.C. Joplin Rapamycin inhibits corneal allograft rejection and neovascularization Arch Ophthalmol 112 11 1994 1471 1475
21. S.M. Flechner, S.M. Kurian, and K. Solez De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years Am J Transplant 4 12 2004 1776 1785
22. E. Daniel, J.E. Thorne, and C.W. Newcomb Mycophenolate mofetil for ocular inflammation Am J Ophthalmol 149 3 2010 423 432
23. J.J. Augustine, T.C. Knauss, and J.A. Schulak Comparative effect of sirolimus and mycophenolate mofetil on erythrpoeisis in kidney transplant patients Am J Transplant 4 12 2004 2001 2006